期刊文献+

风湿骨痹口服液急性毒性研究

Acute Toxicity of Fengshigubi Oral Liquid
下载PDF
导出
摘要 目的观察小鼠灌胃风湿骨痹口服液的急性毒性反应,测定半数致死量(LD50)及最大给药量,为临床安全用药提供依据。方法小鼠给予风湿骨痹口服液灌胃,通过预试验测定LD50及最大给药量。结果 LD50未测出;小鼠最大给药量为1 236 g生药/kg,相当于临床人用量的1 799倍,在此剂量下灌胃对小鼠无急性毒性反应。结论风湿骨痹口服液毒性较低,在临床规定用法用量下安全可靠。 Objective To observe the acute toxicity reaction of Fengshigubi Oral Liquid by gastric gavage in mice,and to determine LD50 and the maximum dosage to provide the basis for clinical safe medication. Methods The mice were given Fengshigubi Oral Liquid by gastric gavage. The median lethal dose(LD50) and the maximum dose were determined by the pre- experiment. Results LD50 was not detected out and the maximum dose in mice was 1236 g crude drug/kg,which was equivalent to 1799 times of human dosage in clinic,the gastric gavage of this dose had no acute toxicity in mice. Conclusion Fengshigubi Oral Liquid has low toxicity and it is safe under the clinical provision of usage and dosage.
作者 辛玲歌
出处 《中国药业》 CAS 2014年第24期29-30,共2页 China Pharmaceuticals
基金 陕西省咸阳市2012科技计划项目 项目编号:2012k16-04
关键词 风湿骨痹口服液 急性毒性试验 半数致死量 最大给药量 Fengshigubi Oral Liquid acute toxicity tests median lethal dose maximum dose
  • 相关文献

参考文献5

二级参考文献22

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部